US4272549A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutical method for the treatment of chronic uraemic patients undergoing periodical haemodialysis and liquid composition for dialysis for use in such a method
Assignee: Individual
•
Filing: 1979-05-14
•
Granted: 1981-06-09
•
Expires: 1999-05-14
Abstract
Abstract A therapeutical method for treating uraemic patients in regular dialysis treatment (RDT) is disclosed, wherein carnitine is administered to the patients. Carnitine can be administered over the whole treatment period by the oral route exclusively. Alternatively, while oral administration is carried out only in those days in which the patient is not subjected to dialysis, when the patient undergoes dialysis, a carnitine-containing dialyzing liquid is used. Furthermore, a suitable dialyzing solution is also disclosed.
Inventors
- 👤 Claudio Cavazza
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:56
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K31/22; A61K31/23; A61P; A61P13/00; A61P13/02; A61P15/00; A61M; A61M1/00; A61M1/14; A61M1/16; A61M1/1654
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
69 words
A method for alleviating asthenia and muscle weakness in a chronic uraemic patient under regular dialysis treatment, which comprises submitting said patient to dialysis with a polysaline dialytic solution which contains a quantity of carnitine, or a pharmaceutically acceptable salt thereof, sufficient to render the molar concentration of carnitine in said solution at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment.
Claim 2
Independent Claim
69 words
A method for alleviating asthenia and muscle weakness in a chronic uraemic patient under regular dialysis treatment, which comprises submitting said patient to dialysis with a polysaline dialytic solution which contains a quantity of carnitine, or a pharmaceutically acceptable salt thereof, sufficient to render the molar concentration of carnitine in said solution at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment.
Claim 3
Dependent Claim
29 words
The method according to claim 1 wherein the concentration of carnitine in said dialytic solution is substantially equimolar to the concentration of carnitine in the plasma of said patient.
Claim 4
Dependent Claim
26 words
The method according to claim 1 wherein the concentration of carnitine in said dialytic solution is from 50 mole to 100 μmole per liter of solution.
Claim 5
Dependent Claim
37 words
The method according to claim 1 wherein there is administered to said uraemic patient on the day of said haemodialysis from 3 to 6 grams of carnitine or an equivalent amount of a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
12 words
The method according to claim 4 wherein said carnitine is administered orally.
Claim 7
Dependent Claim
14 words
The method according to claim 4 wherein said carnitine is administered by slow infusion.
Claim 8
Dependent Claim
51 words
The method according to claim 1 wherein from 3 to 6 grams of carnitine or an equivalent amount of a pharmaceutically acceptable salt thereof is orally administered to said patients on days between haemodialysis from 3 to 6 grams of carnitine/day or an equivalent amount of a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
80 words
A polysaline dialytic solution for use in the dialysis of chronic uraemic patients which contains, per liter of solution, from 140 to 145 mEq of sodium ions, from 0.8 to 1.2 mEq of potassium ions, from 3.2 to 3.8 mEq of calcium ions, from 1.2 to 1.8 mEq of magnesium ions, from 35 to 40 mEq of chloride ions, from 0.95 to 1.05 mEq of glucose and from 50 to 100 μmoles of carnitine or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
80 words
A polysaline dialytic solution for use in the dialysis of chronic uraemic patients which contains, per liter of solution, from 140 to 145 mEq of sodium ions, from 0.8 to 1.2 mEq of potassium ions, from 3.2 to 3.8 mEq of calcium ions, from 1.2 to 1.8 mEq of magnesium ions, from 35 to 40 mEq of chloride ions, from 0.95 to 1.05 mEq of glucose and from 50 to 100 μmoles of carnitine or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
56 words
In a polysaline haemodialysis solution concentrate the improvement which consists of an amount of carnitine or a pharmaceutically acceptable salt thereof sufficient, upon dilution of said concentrate to produce a ready-for-use polysaline haemodialysis solution, with a carnitine molar concentration at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment.
Claim 12
Dependent Claim
56 words
In a polysaline haemodialysis solution concentrate the improvement which consists of an amount of carnitine or a pharmaceutically acceptable salt thereof sufficient, upon dilution of said concentrate to produce a ready-for-use polysaline haemodialysis solution, with a carnitine molar concentration at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment.
Claim 13
Dependent Claim
40 words
The concentrate according to claim 9 wherein the amount of carnitine or a pharmaceutically acceptable salt thereof is sufficient, upon said dilution, to yield a concentration of carnitine equimolar to that in the blood of the patient under dialytic treatment.
Claim 14
Dependent Claim
33 words
The concentrate according to claim 9 wherein the amount of carnitine or a pharmaceutically acceptable salt thereof is sufficient, upon said dilution, to yield a carnitine concentration of from 50 to 100 μmoles/liter.
Claim 15
Dependent Claim
44 words
The concentrated solution of claim 11, comprising: ______________________________________
sodium chloride 210-215 g/l
sodium acetate trihydrate
178-182 g/l
magnesium chloride hexahydrate
4.8-5.5 g/l
calcium chloride hexahydrate
12.5-14 g/l
potassium chloride 2.5-2.7 g/l
anhydrous glucose 34-36 g/l
carnitine or pharmaceutically
acceptable salt thereof
1750-3500 μmoles/l
______________________________________
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-06-08 | 1984-12-08 | 1985-06-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-06-08 | 1988-12-08 | 1989-06-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-06-08 | 1992-12-08 | 1993-06-09 | $7700.00 | Window Closed / Lapsed |